Curated News
By: NewsRamp Editorial Staff
May 27, 2026

Cardio Diagnostics to Showcase AI Heart Risk Tools at Benefits Conferences

Discuss on Substack
Original Source

TLDR

  • Cardio Diagnostics' AI tools help employers reduce healthcare costs by catching cardiovascular disease early.
  • Cardio Diagnostics uses AI-powered genetic-epigenetic tests like Epi+Gen CHD to assess cardiovascular risk accurately.
  • By identifying at-risk individuals earlier, Cardio Diagnostics helps improve health outcomes and reduce suffering.
  • Cardio Diagnostics will showcase its AI heart risk platform at four national benefits conferences in June.

Impact - Why it Matters

This news matters because cardiovascular disease is a leading cause of healthcare spending and lost productivity for employers. Cardio Diagnostics' AI-powered assessments could help companies identify at-risk employees earlier, potentially reducing costs and improving health outcomes. For benefits decision-makers, this represents an opportunity to adopt innovative, data-driven strategies for managing one of the most significant health and financial risks in the workplace.

Summary

LOS ANGELES, CA - May 27, 2026 (NEWMEDIAWIRE) - Cardio Diagnostics Holdings (NASDAQ: CDIO) is set to make a significant impact at four national benefits conferences this June, targeting employers, brokers, union trustees, and plan administrators. The company aims to address cardiovascular disease, which is a leading driver of health plan costs and workforce productivity losses. Cardio Diagnostics will showcase its AI-powered cardiovascular risk assessment offerings, including Epi+Gen CHD, PrecisionCHD, and the HeartRisk population insights platform. These tools are designed to identify at-risk individuals earlier, helping benefits decision-makers better manage healthcare costs and outcomes.

Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary AI-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease, aiming to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. By attending these conferences, Cardio Diagnostics hopes to engage key stakeholders and demonstrate how its innovative solutions can transform cardiovascular care.

The conferences provide a platform for Cardio Diagnostics to connect with decision-makers who are actively seeking strategies to reduce healthcare costs and improve employee health. With cardiovascular disease remaining a top concern for employers and insurers, the company's AI-driven assessments offer a proactive approach to risk identification and management. For more details, visit the full press release at https://ibn.fm/qFRHu. The latest news and updates relating to CDIO are also available in the company’s newsroom at https://ibn.fm/CDIO.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Cardio Diagnostics to Showcase AI Heart Risk Tools at Benefits Conferences

blockchain registration record for this content.